title: [Use of dalargin in the intensive therapy of critical conditions].
abstract: The paper analyzes whether the national synthetic leukenkephalin analogue dalargin can be used in the prevention and treatment of postoperative polyorgan deficiency. Dalargin has been experimentally demonstrated to be effective in preventing impairments in transcapillary fluid exchange, by stopping the development of pulmonary edema. The use of the drug in the intra- and postoperative period in patients undergone cardiac surgery during general assisted circulation reduced the incidence substantially and decreased the severity of respiratory distress syndrome. The experimental and clinical findings suggest that dalargin has pulmono-, hepato-, and pancreatoprotective properties. Thus, dalargin should be used in the multimodality intensive care of postoperative polyorgan deficiency.
authors.forename: V I
authors.initials: VI
authors.lastname: Smirnova
authors.forename: N N
authors.initials: NN
authors.lastname: Pulina
authors.forename: V V
authors.initials: VV
authors.lastname: Kazennov
authors.forename: A V
authors.initials: AV
authors.lastname: Oranskiĭ
authors.forename: E P
authors.initials: EP
authors.lastname: Smirnov
mesh_terms: D000818:Animals; D003422:Critical Care / Q000379:methods*; D004630:Emergencies; D016308:Enkephalin, Leucine-2-Alanine / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D005260:Female; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D008297:Male; D011183:Postoperative Complications / Q000188:drug therapy* / Q000503:physiopathology; D051381:Rats; D013565:Sympatholytics / Q000494:pharmacology / Q000627:therapeutic use*
chemical_list: D013565:Sympatholytics; D016308:Enkephalin, Leucine-2-Alanine; C040996:enkephalin-Leu, Ala(2)-Arg(6)-